Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holding Ltd ADR (RHHBY)

Roche Holding Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 307,760,704
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 76,471 M
  • Annual Income, $ 15,546 M
  • EBIT $ 0 M
  • EBITDA $ 26,387 M
  • 60-Month Beta 0.44
  • Price/Sales 4.06
  • Price/Cash Flow 13.53
  • Price/Book 6.79
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26
  • Annual Dividend & Yield (Fwd) 1.00 (2.05%)
  • Most Recent Dividend 1.001 on 03/13/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.0500 +3.97%
on 03/20/26
58.4300 -16.28%
on 03/02/26
-10.6300 (-17.85%)
since 02/27/26
3-Month
47.0500 +3.97%
on 03/20/26
60.8500 -19.61%
on 02/24/26
-3.5800 (-6.82%)
since 12/26/25
52-Week
34.7500 +40.78%
on 04/09/25
60.8500 -19.61%
on 02/24/26
+7.0000 (+16.70%)
since 03/28/25

Most Recent Stories

More News
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets

PLEASANTON, Calif. , March 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas ® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test...

ROP : 350.97 (+1.90%)
RHHBY : 48.8350 (+1.09%)
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation

INDIANAPOLIS , March 18, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S . Food and Drug Administration (FDA) has categorized its Ionify® steroid assays...

ROG : 105.81 (-3.22%)
RHHBY : 48.8350 (+1.09%)
Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

BASEL, Switzerland , March 16, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark approval for its Elecsys ® Apolipoprotein E4 biomarker test...

ROG : 105.81 (-3.22%)
RHHBY : 48.8350 (+1.09%)
3 ETFs to Avoid as Oil Shock Hits Markets

With oil prices soaring near $100 per barrel, certain sectors are feeling more pain than others. Here are three ETFs to avoid amid oil's market roil.

LVMUY : 105.8640 (+1.58%)
TRIP : 10.22 (+1.09%)
TSLA : 357.14 (-1.30%)
SAP : 168.58 (+2.78%)
XLY : 105.81 (+0.12%)
JETS : 23.63 (-2.07%)
EXPE : 227.98 (+0.96%)
NVS : 150.30 (+1.43%)
VGK : 79.88 (+0.54%)
RHHBY : 48.8350 (+1.09%)
AMZN : 201.70 (+1.18%)
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed ...

RHHBY : 48.8350 (+1.09%)
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms ...

RHHBY : 48.8350 (+1.09%)
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

– Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value

RHHBY : 48.8350 (+1.09%)
New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

BASEL, Switzerland , March 5, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today findings from a global survey of 4,326 people with diabetes across 22 countries, exploring the...

RHHVF : 393.9000 (+1.00%)
ROG : 105.81 (-3.22%)
RHHBY : 48.8350 (+1.09%)
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with...

RHHBY : 48.8350 (+1.09%)
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands Genentech’s...

RHHBY : 48.8350 (+1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 50.2433
2nd Resistance Point 49.7967
1st Resistance Point 49.0533
Last Price 48.8350
1st Support Level 47.8633
2nd Support Level 47.4167
3rd Support Level 46.6733

See More

52-Week High 60.8500
Fibonacci 61.8% 50.8798
Last Price 48.8350
Fibonacci 50% 47.8000
Fibonacci 38.2% 44.7202
52-Week Low 34.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.